Reyataz label
Interaction Color Code
Clinical Bottom Line
Adjust dosing to avoid reduced levels of atazanavir
Drug 1
Drug 1 dose
400 mg daily
Drug 1 effect
Atazanavir AUC decreased 94%, Cmax decreased 91%, half-life: no significant change
Drug 2
Drug 2 dose
60 mg daily x 2 doses
Clinical Effects
Potential loss of antiretroviral efficacy
Management
Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients.
Alternative Agents
H2 receptor antagonists
Import ID
785
